Review

human oscc cell lines scc4 (ATCC)

ATCC is a verified supplier

ATCC manufactures this product

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

ATCC human oscc cell lines scc4
Human Oscc Cell Lines Scc4, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 749 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+cell+lines+scc4/pm41981604-125-0-5?v=ATCC
Average 96 stars, based on 749 article reviews

human oscc cell lines scc4 - by Bioz Stars, 2026-08

96/100 stars

Images

Image Search Results

Characterization of SCC4-EGFP spheroids with different volumes. (A) Structure of the dual-function antibody conjugate. The number of BPD and SiNC(OH) molecules per antibody molecule are denoted by “ x ” and “ y ”, respectively. (B) Graph representing the change in SCC4-EGFP spheroid volume on different days, post cell-seeding. (C) Representative images of SCC4-EGFP 3D spheroids formed with different cell numbers (2500, 5000, 10,000, and 25,000 cells). Cell numbers are mentioned at the top, while spheroid volumes are mentioned within the images (scale bar = 500 μm).

Journal: Bioconjugate Chemistry

Article Title: Dual-Function Antibody Conjugate-Enabled Photoimmunotherapy Complements Fluorescence and Photoacoustic Imaging of Head and Neck Cancer Spheroids

doi: 10.1021/acs.bioconjchem.3c00406

Figure Lengend Snippet: Characterization of SCC4-EGFP spheroids with different volumes. (A) Structure of the dual-function antibody conjugate. The number of BPD and SiNC(OH) molecules per antibody molecule are denoted by “ x ” and “ y ”, respectively. (B) Graph representing the change in SCC4-EGFP spheroid volume on different days, post cell-seeding. (C) Representative images of SCC4-EGFP 3D spheroids formed with different cell numbers (2500, 5000, 10,000, and 25,000 cells). Cell numbers are mentioned at the top, while spheroid volumes are mentioned within the images (scale bar = 500 μm).

Article Snippet: Human oral squamous cell carcinoma line SCC4 was obtained from American Type Culture Collection (ATCC CRL-1624, Manassas, VA).

Techniques:

Fluorescence imaging of DFAC-treated SCC4 spheroids. (A) Experimental scheme of SCC4-EGFP 3D spheroid treatment with DFAC and imaging. (B) IVIS fluorescence imaging of DFAC-treated SCC4 spheroids prepared as gelatin-embedded tissue-mimicking phantoms in a 96-well plate (scale bar = 2.5 mm). Cell numbers and volumes are mentioned at the top, while DFAC concentrations (SiNC(OH) equivalent) are mentioned on the left. (C) Quantification of fluorescence signals from the IVIS images is represented as the tumor spheroid-to-background ratio. Data are presented as mean ± SD ( n ≥ 3), analyzed using one-way ANOVA with Tukey’s test for post hoc analysis. p -Values <0.05 were considered to be significant and are indicated by asterisks as follows: ns p > 0.05, * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001.

Journal: Bioconjugate Chemistry

Article Title: Dual-Function Antibody Conjugate-Enabled Photoimmunotherapy Complements Fluorescence and Photoacoustic Imaging of Head and Neck Cancer Spheroids

doi: 10.1021/acs.bioconjchem.3c00406

Figure Lengend Snippet: Fluorescence imaging of DFAC-treated SCC4 spheroids. (A) Experimental scheme of SCC4-EGFP 3D spheroid treatment with DFAC and imaging. (B) IVIS fluorescence imaging of DFAC-treated SCC4 spheroids prepared as gelatin-embedded tissue-mimicking phantoms in a 96-well plate (scale bar = 2.5 mm). Cell numbers and volumes are mentioned at the top, while DFAC concentrations (SiNC(OH) equivalent) are mentioned on the left. (C) Quantification of fluorescence signals from the IVIS images is represented as the tumor spheroid-to-background ratio. Data are presented as mean ± SD ( n ≥ 3), analyzed using one-way ANOVA with Tukey’s test for post hoc analysis. p -Values <0.05 were considered to be significant and are indicated by asterisks as follows: ns p > 0.05, * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001.

Article Snippet: Human oral squamous cell carcinoma line SCC4 was obtained from American Type Culture Collection (ATCC CRL-1624, Manassas, VA).

Techniques: Fluorescence, Imaging

Photoacoustic imaging of DFAC-treated SCC4 spheroids. (A) Photoacoustic imaging of DFAC-treated SCC4 spheroids prepared as gelatin-embedded tissue-mimicking phantoms in a 96-well plate (scale bar = 2.5 mm). Cell numbers and volumes are mentioned on the left, while DFAC concentrations (SiNC(OH) equivalent) are mentioned on the top. (B) Quantification of photoacoustic signals from the images represented as the normalized photoacoustic signal intensity per mm 3 . Data are presented as mean ± SD ( n ≥ 3), analyzed using one-way Brown–Forsythe and Welch ANOVA test with post hoc analysis. p -Values <0.05 were considered to be significant and are indicated by asterisks as follows: ns p > 0.05, * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001.

Journal: Bioconjugate Chemistry

Article Title: Dual-Function Antibody Conjugate-Enabled Photoimmunotherapy Complements Fluorescence and Photoacoustic Imaging of Head and Neck Cancer Spheroids

doi: 10.1021/acs.bioconjchem.3c00406

Figure Lengend Snippet: Photoacoustic imaging of DFAC-treated SCC4 spheroids. (A) Photoacoustic imaging of DFAC-treated SCC4 spheroids prepared as gelatin-embedded tissue-mimicking phantoms in a 96-well plate (scale bar = 2.5 mm). Cell numbers and volumes are mentioned on the left, while DFAC concentrations (SiNC(OH) equivalent) are mentioned on the top. (B) Quantification of photoacoustic signals from the images represented as the normalized photoacoustic signal intensity per mm 3 . Data are presented as mean ± SD ( n ≥ 3), analyzed using one-way Brown–Forsythe and Welch ANOVA test with post hoc analysis. p -Values <0.05 were considered to be significant and are indicated by asterisks as follows: ns p > 0.05, * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001.

Article Snippet: Human oral squamous cell carcinoma line SCC4 was obtained from American Type Culture Collection (ATCC CRL-1624, Manassas, VA).

Techniques: Imaging

Long-term response of SCC4 spheroids to DFAC-mediated PIT. (top) Experimental schedule for the long-term response of SCC4 spheroids to PIT. Cells were seeded in CellCarrier Spheroid ULA 96-well microplates, followed by incubation with DFAC for 24 h. The spheroids were then irradiated with varying light doses of 10–100 J/cm 2 , followed by imaging for 5 weeks. (bottom left) Maximum intensity projection (MIP) of fluorescence signals from SCC4 spheroids on day 31 post-PDT. Scale bar corresponds to 500 μm. (bottom right) Relative viability of SCC4 spheroids treated with PIT is shown in the right panel.

Journal: Bioconjugate Chemistry

Article Title: Dual-Function Antibody Conjugate-Enabled Photoimmunotherapy Complements Fluorescence and Photoacoustic Imaging of Head and Neck Cancer Spheroids

doi: 10.1021/acs.bioconjchem.3c00406

Figure Lengend Snippet: Long-term response of SCC4 spheroids to DFAC-mediated PIT. (top) Experimental schedule for the long-term response of SCC4 spheroids to PIT. Cells were seeded in CellCarrier Spheroid ULA 96-well microplates, followed by incubation with DFAC for 24 h. The spheroids were then irradiated with varying light doses of 10–100 J/cm 2 , followed by imaging for 5 weeks. (bottom left) Maximum intensity projection (MIP) of fluorescence signals from SCC4 spheroids on day 31 post-PDT. Scale bar corresponds to 500 μm. (bottom right) Relative viability of SCC4 spheroids treated with PIT is shown in the right panel.

Article Snippet: Human oral squamous cell carcinoma line SCC4 was obtained from American Type Culture Collection (ATCC CRL-1624, Manassas, VA).

Techniques: Incubation, Irradiation, Imaging, Fluorescence

Recurrence of SCC4 spheroid growth after DFAC-mediated PIT. SCC4 spheroids with different volumes were treated with PIT with different light doses: (A) 5 J/cm 2 , (B) 25 J/cm 2 , (C) 50 J/cm 2 , and (D) 100 J/cm 2 .

Journal: Bioconjugate Chemistry

Article Title: Dual-Function Antibody Conjugate-Enabled Photoimmunotherapy Complements Fluorescence and Photoacoustic Imaging of Head and Neck Cancer Spheroids

doi: 10.1021/acs.bioconjchem.3c00406

Figure Lengend Snippet: Recurrence of SCC4 spheroid growth after DFAC-mediated PIT. SCC4 spheroids with different volumes were treated with PIT with different light doses: (A) 5 J/cm 2 , (B) 25 J/cm 2 , (C) 50 J/cm 2 , and (D) 100 J/cm 2 .

Article Snippet: Human oral squamous cell carcinoma line SCC4 was obtained from American Type Culture Collection (ATCC CRL-1624, Manassas, VA).

Techniques:

The pattern of mRNA expression of the IGF2BPs gene family in pan-cancer and HNSCC. (a) The pattern of mRNA expression of the IGF2BPs gene family in pan-cancer in TCGA database. (b) The 3D protein structure of the IGF2BPs gene family. (c–d) The pattern of mRNA expression of the IGF2BPs gene family in HNSCC in TCGA database using paired and unpaired sample analysis.

Journal: Heliyon

Article Title: Comprehensive analysis of the expression of the IGF2BPs gene family in head and neck squamous cell carcinoma: Association with prognostic value and tumor immunity

doi: 10.1016/j.heliyon.2023.e20659

Figure Lengend Snippet: The pattern of mRNA expression of the IGF2BPs gene family in pan-cancer and HNSCC. (a) The pattern of mRNA expression of the IGF2BPs gene family in pan-cancer in TCGA database. (b) The 3D protein structure of the IGF2BPs gene family. (c–d) The pattern of mRNA expression of the IGF2BPs gene family in HNSCC in TCGA database using paired and unpaired sample analysis.

Article Snippet: The human HNSCC cell line SCC4 was obtained from the American Type Culture Collection (ATCC) and cultured in DMEM (Gibco, USA) medium supplemented with 10 % fetal bovine serum(Gibco, USA) and 1 % penicillin-streptomycin(Gibco, USA) at 37 °C and 5 % CO2 in a cell culture incubator.

Techniques: Expressing

The protein expression level of the IGF2BPs gene family in HNSCC and healthy control tissues in the HPA database. Immunohistochemical profiles showed the protein level of expression of the IGF2BPs gene family in HNSCC with significantly higher expression compared to healthy tissues.

Journal: Heliyon

Article Title: Comprehensive analysis of the expression of the IGF2BPs gene family in head and neck squamous cell carcinoma: Association with prognostic value and tumor immunity

doi: 10.1016/j.heliyon.2023.e20659

Figure Lengend Snippet: The protein expression level of the IGF2BPs gene family in HNSCC and healthy control tissues in the HPA database. Immunohistochemical profiles showed the protein level of expression of the IGF2BPs gene family in HNSCC with significantly higher expression compared to healthy tissues.

Techniques: Expressing, Control, Immunohistochemical staining

The diagnostic values of the IGF2BPs gene family in HNSCC were evaluated using ROC curves. The AUC area of the ROC curve above 0.9 represents a high accuracy in predicting HNSCC. (a–c) shows that the diagnostic values of the IGF2BPs gene family in HNSCC all have high accuracy.

Journal: Heliyon

Article Title: Comprehensive analysis of the expression of the IGF2BPs gene family in head and neck squamous cell carcinoma: Association with prognostic value and tumor immunity

doi: 10.1016/j.heliyon.2023.e20659

Figure Lengend Snippet: The diagnostic values of the IGF2BPs gene family in HNSCC were evaluated using ROC curves. The AUC area of the ROC curve above 0.9 represents a high accuracy in predicting HNSCC. (a–c) shows that the diagnostic values of the IGF2BPs gene family in HNSCC all have high accuracy.

Techniques: Diagnostic Assay

Survival analysis findings of the IGF2BPs gene family in pan-cancer and HNSCC. (a–b) The survival map illustrated the prognosis-predictive values of the IGF2BPs gene family in overall survival (OS) and disease-free survival (DFS) of multiple pan-cancer. (c) The IGF2BPs gene family and three prognostic outcomes—disease-specific survival (DSS), progression-free interval survival (PFI), and overall survival (OS) in individuals with HNSCC—were correlated, as shown by the Kaplan-Meier curves.

Journal: Heliyon

Article Title: Comprehensive analysis of the expression of the IGF2BPs gene family in head and neck squamous cell carcinoma: Association with prognostic value and tumor immunity

doi: 10.1016/j.heliyon.2023.e20659

Figure Lengend Snippet: Survival analysis findings of the IGF2BPs gene family in pan-cancer and HNSCC. (a–b) The survival map illustrated the prognosis-predictive values of the IGF2BPs gene family in overall survival (OS) and disease-free survival (DFS) of multiple pan-cancer. (c) The IGF2BPs gene family and three prognostic outcomes—disease-specific survival (DSS), progression-free interval survival (PFI), and overall survival (OS) in individuals with HNSCC—were correlated, as shown by the Kaplan-Meier curves.

Techniques:

Forrest plots revealed the correlation between the clinical features and the IGF2BPs gene family in HNSCC. (a) The Univariate Cox regression analyses. (b) The multivariate Cox regression analyses.

Journal: Heliyon

Article Title: Comprehensive analysis of the expression of the IGF2BPs gene family in head and neck squamous cell carcinoma: Association with prognostic value and tumor immunity

doi: 10.1016/j.heliyon.2023.e20659

Figure Lengend Snippet: Forrest plots revealed the correlation between the clinical features and the IGF2BPs gene family in HNSCC. (a) The Univariate Cox regression analyses. (b) The multivariate Cox regression analyses.

Techniques:

The nomogram and calibration plots. (a) The nomogram plots were utilized to assess the OS over 1, 3, and 5 years for HNSCC patients. (C) The calibration plots were utilized to predict the accuracy of the nomogram model of 1, 3, and 5- years.

Journal: Heliyon

Article Title: Comprehensive analysis of the expression of the IGF2BPs gene family in head and neck squamous cell carcinoma: Association with prognostic value and tumor immunity

doi: 10.1016/j.heliyon.2023.e20659

Figure Lengend Snippet: The nomogram and calibration plots. (a) The nomogram plots were utilized to assess the OS over 1, 3, and 5 years for HNSCC patients. (C) The calibration plots were utilized to predict the accuracy of the nomogram model of 1, 3, and 5- years.

Techniques:

The co-expressed and associated genes of the IGF2BPs gene family. (a) Gene-gene interaction (GGI) network. (b) Top 10 genes positively and negatively correlated with IGF2BPs gene family in HNSCC.

Journal: Heliyon

Article Title: Comprehensive analysis of the expression of the IGF2BPs gene family in head and neck squamous cell carcinoma: Association with prognostic value and tumor immunity

doi: 10.1016/j.heliyon.2023.e20659

Figure Lengend Snippet: The co-expressed and associated genes of the IGF2BPs gene family. (a) Gene-gene interaction (GGI) network. (b) Top 10 genes positively and negatively correlated with IGF2BPs gene family in HNSCC.

Techniques:

The link between the IGF2BPs gene family and tumor microenvironment by evaluation of the Estimate-Immune-Stromal score in HNSCC. (a–c) Scatter plots revealed a significant negative correlation between the IGF2BPs gene family and the estimate score. (d–f) Scatter plots showed that there is no significant correlation between the IGF2BPs gene family and the stromal score. (g–i) Scatter plot illustrated the obvious negative correlation between IGF2BPs gene family and immune score.

Journal: Heliyon

Article Title: Comprehensive analysis of the expression of the IGF2BPs gene family in head and neck squamous cell carcinoma: Association with prognostic value and tumor immunity

doi: 10.1016/j.heliyon.2023.e20659

Figure Lengend Snippet: The link between the IGF2BPs gene family and tumor microenvironment by evaluation of the Estimate-Immune-Stromal score in HNSCC. (a–c) Scatter plots revealed a significant negative correlation between the IGF2BPs gene family and the estimate score. (d–f) Scatter plots showed that there is no significant correlation between the IGF2BPs gene family and the stromal score. (g–i) Scatter plot illustrated the obvious negative correlation between IGF2BPs gene family and immune score.

Techniques:

The link between the IGF2BPs gene family and tumor immunity in HNSCC. (a) The link between immune cell infiltration and the IGF2BPs gene family in HNSCC. (b) The link between immune inhibitory/stimulatory genes and the IGF2BPs gene family in HNSCC.

Journal: Heliyon

Article Title: Comprehensive analysis of the expression of the IGF2BPs gene family in head and neck squamous cell carcinoma: Association with prognostic value and tumor immunity

doi: 10.1016/j.heliyon.2023.e20659

Figure Lengend Snippet: The link between the IGF2BPs gene family and tumor immunity in HNSCC. (a) The link between immune cell infiltration and the IGF2BPs gene family in HNSCC. (b) The link between immune inhibitory/stimulatory genes and the IGF2BPs gene family in HNSCC.

Techniques:

The proliferation, migration, and invasion capacities of the SCC4 cell line were inhibited by the knockdown of IGF2BP2 expression. (a) IGF2BP2 is highly expressed in HNSCC cell lines relative to non-malignant oral cells (HOK). (b–c) The expression of IGF2BP2 in the SCC4 cell line was knocked down by siRNA and the knockdown efficiency was verified by RT-qPCR and Western blot assays. (d–e) CCK8 and EDU proliferation assays revealed that the knockdown of IGF2BP2 expression considerably inhibited the proliferation behavior in SCC4 cell lines compared to si-NC. (f) Wound healing assay demonstrated that knockdown of IGF2BP2 expression significantly inhibited migration behavior in the SCC4 cell line compared to si-NC. (g) Transwell assay showed that knockdown of IGF2BP2 expression significantly inhibited migration and invasion behavior in the SCC4 cell line compared to si-NC. (*p < 0.05, **p < 0.01, and ***p < 0.001).

Journal: Heliyon

Article Title: Comprehensive analysis of the expression of the IGF2BPs gene family in head and neck squamous cell carcinoma: Association with prognostic value and tumor immunity

doi: 10.1016/j.heliyon.2023.e20659

Figure Lengend Snippet: The proliferation, migration, and invasion capacities of the SCC4 cell line were inhibited by the knockdown of IGF2BP2 expression. (a) IGF2BP2 is highly expressed in HNSCC cell lines relative to non-malignant oral cells (HOK). (b–c) The expression of IGF2BP2 in the SCC4 cell line was knocked down by siRNA and the knockdown efficiency was verified by RT-qPCR and Western blot assays. (d–e) CCK8 and EDU proliferation assays revealed that the knockdown of IGF2BP2 expression considerably inhibited the proliferation behavior in SCC4 cell lines compared to si-NC. (f) Wound healing assay demonstrated that knockdown of IGF2BP2 expression significantly inhibited migration behavior in the SCC4 cell line compared to si-NC. (g) Transwell assay showed that knockdown of IGF2BP2 expression significantly inhibited migration and invasion behavior in the SCC4 cell line compared to si-NC. (*p < 0.05, **p < 0.01, and ***p < 0.001).

Techniques: Migration, Knockdown, Expressing, Quantitative RT-PCR, Western Blot, Wound Healing Assay, Transwell Assay

CX3CL1 was upregulated in oral squamous cell carcinoma (OSCC) tissue and associated with clinical disease stages in human OSCC. (A) Correlation CX3CL1 gene expression with the normal and tumour cells using GEO microarray 3524 OSCC tissue samples. (B) CX3CL1 expression profiles in 497 OSCC tissue specimens were analysed obtained from the Cancer Genome Atlas (TCGA) database. (C,D) OSCC specimens were subjected to IHC staining. (E) Kaplan–Meier survival analysis of the associations between high or low plasma levels of CX3CL1 expression and overall survival of OSCC patients. * p < 0.05 compared with controls.

Journal: Journal of Cellular and Molecular Medicine

Article Title: CX3CL1 induces cell migration and invasion through ICAM ‐1 expression in oral squamous cell carcinoma cells

doi: 10.1111/jcmm.17750

Figure Lengend Snippet: CX3CL1 was upregulated in oral squamous cell carcinoma (OSCC) tissue and associated with clinical disease stages in human OSCC. (A) Correlation CX3CL1 gene expression with the normal and tumour cells using GEO microarray 3524 OSCC tissue samples. (B) CX3CL1 expression profiles in 497 OSCC tissue specimens were analysed obtained from the Cancer Genome Atlas (TCGA) database. (C,D) OSCC specimens were subjected to IHC staining. (E) Kaplan–Meier survival analysis of the associations between high or low plasma levels of CX3CL1 expression and overall survival of OSCC patients. * p < 0.05 compared with controls.

Article Snippet: Three human OSCC cell lines (SCC4, SCC25 and SAS cells) were acquired from the Bioresource Collection and Research Center (BCRC).

Techniques: Gene Expression, Microarray, Expressing, Immunohistochemistry, Clinical Proteomics

CX3CL1 upregulates human oral squamous cell carcinoma (OSCC) cell migration and invasion. (A‐C) OSCC cells were incubated with different concentrations of CX3CL1 for 24 h; then, cell migration was assessed using the (A) in vitro wound‐healing assay, (B,C) the Transwell assay. (D) Quantified result of cell migration with CX3CL1 neutralizing antibody. (E) Quantified result of cell invasion with CX3CL1 neutralizing antibody. Results are expressed as the mean ± SD of four independent experiments. * p < 0.05 as compared with controls.

Journal: Journal of Cellular and Molecular Medicine

Article Title: CX3CL1 induces cell migration and invasion through ICAM ‐1 expression in oral squamous cell carcinoma cells

doi: 10.1111/jcmm.17750

Figure Lengend Snippet: CX3CL1 upregulates human oral squamous cell carcinoma (OSCC) cell migration and invasion. (A‐C) OSCC cells were incubated with different concentrations of CX3CL1 for 24 h; then, cell migration was assessed using the (A) in vitro wound‐healing assay, (B,C) the Transwell assay. (D) Quantified result of cell migration with CX3CL1 neutralizing antibody. (E) Quantified result of cell invasion with CX3CL1 neutralizing antibody. Results are expressed as the mean ± SD of four independent experiments. * p < 0.05 as compared with controls.

Article Snippet: Three human OSCC cell lines (SCC4, SCC25 and SAS cells) were acquired from the Bioresource Collection and Research Center (BCRC).

Techniques: Migration, Incubation, In Vitro, Wound Healing Assay, Transwell Assay

CX3CL1 activates tumour cell migration via the ICAM‐1 expression in human oral squamous cell carcinoma (OSCC) cells. (A) ICAM‐1 expression in the normal and tumour cells obtained from the TCGA dataset analysis. (B) VCAM‐1 expression in the normal and tumour cells obtained from the TCGA dataset analysis. (C) Correlation analysis of CX3CL1 and ICAM‐1 expression using the TIMER2.0 database. (D) Correlation analysis of CX3CL1 and VCAM‐1 expression using the TIMER2.0 database. (E) Quantified result of ICAM‐1 gene expression with CX3CL1 recombinant protein (30 ng/mL) treatment. (F) Quantified result of VCAM‐1 gene expression with CX3CL1 recombinant protein (30 ng/mL) treatment. (G) Protein expression of ICAM‐1 with concentration‐depended CX3CL1 treatment. (H) Protein expression of VCAM‐1 with concentration‐depended CX3CL1 treatment. (I) Quantified result of cell migration with ICAM‐1 siRNA and CX3CL1 recombinant protein (30 ng/mL) treatment. (J) Quantified result of cell migration with ICAM‐1 neutralizing antibody and CX3CL1 recombinant protein (30 ng/mL) treatment. Results are expressed as the mean ± SD of four independent experiments. *, p < 0.05 and #, p < 0.05 as compared to control and CX3CL1 treatment.

Journal: Journal of Cellular and Molecular Medicine

Article Title: CX3CL1 induces cell migration and invasion through ICAM ‐1 expression in oral squamous cell carcinoma cells

doi: 10.1111/jcmm.17750

Figure Lengend Snippet: CX3CL1 activates tumour cell migration via the ICAM‐1 expression in human oral squamous cell carcinoma (OSCC) cells. (A) ICAM‐1 expression in the normal and tumour cells obtained from the TCGA dataset analysis. (B) VCAM‐1 expression in the normal and tumour cells obtained from the TCGA dataset analysis. (C) Correlation analysis of CX3CL1 and ICAM‐1 expression using the TIMER2.0 database. (D) Correlation analysis of CX3CL1 and VCAM‐1 expression using the TIMER2.0 database. (E) Quantified result of ICAM‐1 gene expression with CX3CL1 recombinant protein (30 ng/mL) treatment. (F) Quantified result of VCAM‐1 gene expression with CX3CL1 recombinant protein (30 ng/mL) treatment. (G) Protein expression of ICAM‐1 with concentration‐depended CX3CL1 treatment. (H) Protein expression of VCAM‐1 with concentration‐depended CX3CL1 treatment. (I) Quantified result of cell migration with ICAM‐1 siRNA and CX3CL1 recombinant protein (30 ng/mL) treatment. (J) Quantified result of cell migration with ICAM‐1 neutralizing antibody and CX3CL1 recombinant protein (30 ng/mL) treatment. Results are expressed as the mean ± SD of four independent experiments. *, p < 0.05 and #, p < 0.05 as compared to control and CX3CL1 treatment.

Article Snippet: Three human OSCC cell lines (SCC4, SCC25 and SAS cells) were acquired from the Bioresource Collection and Research Center (BCRC).

Techniques: Migration, Expressing, Gene Expression, Recombinant, Concentration Assay, Control

CX3CL1 upregulates cell motility and ICAM‐1 expression via its receptor CX3CR1. (A) Levels of CX3CR1 mRNA expression in normal tongue tissue and human oral squamous cell carcinoma (OSCC) tumour tissue were analysed using records from the GEO data set GSE13601. (B) Levels of CX3CR1 mRNA expression in different N stages of OSCC tumour tissue were analysed using records from the GEO data set GSE78060. (C) Quantified result of cell movement with CX3CR1 neutralizing antibody and CX3CL1 recombinant protein (30 ng/mL) treatment. (D) Quantified result of cell migration with CX3CR1 neutralizing antibody and CX3CL1 recombinant protein (30 ng/mL) treatment. (E) Quantified resulting of ICAM‐1 expression with CX3CR1 neutralizing antibody and CX3CL1 recombinant protein (30 ng/mL) treatment. (F) Quantified result of cell movement with CX3CR1 siRNA and CX3CL1 recombinant protein (30 ng/mL) treatment. (G) Quantified result of cell migration with CX3CR1 siRNA and CX3CL1 recombinant protein (30 ng/mL) treatment. (H) Quantified result of ICAM‐1 expression with CX3CR1 siRNA and CX3CL1 recombinant protein (30 ng/mL) treatment. Results are expressed as the mean ± SD of four independent experiments. *, p < 0.05 and #, p < 0.05 as compared to control and CX3CL1 treatment.

Journal: Journal of Cellular and Molecular Medicine

Article Title: CX3CL1 induces cell migration and invasion through ICAM ‐1 expression in oral squamous cell carcinoma cells

doi: 10.1111/jcmm.17750

Figure Lengend Snippet: CX3CL1 upregulates cell motility and ICAM‐1 expression via its receptor CX3CR1. (A) Levels of CX3CR1 mRNA expression in normal tongue tissue and human oral squamous cell carcinoma (OSCC) tumour tissue were analysed using records from the GEO data set GSE13601. (B) Levels of CX3CR1 mRNA expression in different N stages of OSCC tumour tissue were analysed using records from the GEO data set GSE78060. (C) Quantified result of cell movement with CX3CR1 neutralizing antibody and CX3CL1 recombinant protein (30 ng/mL) treatment. (D) Quantified result of cell migration with CX3CR1 neutralizing antibody and CX3CL1 recombinant protein (30 ng/mL) treatment. (E) Quantified resulting of ICAM‐1 expression with CX3CR1 neutralizing antibody and CX3CL1 recombinant protein (30 ng/mL) treatment. (F) Quantified result of cell movement with CX3CR1 siRNA and CX3CL1 recombinant protein (30 ng/mL) treatment. (G) Quantified result of cell migration with CX3CR1 siRNA and CX3CL1 recombinant protein (30 ng/mL) treatment. (H) Quantified result of ICAM‐1 expression with CX3CR1 siRNA and CX3CL1 recombinant protein (30 ng/mL) treatment. Results are expressed as the mean ± SD of four independent experiments. *, p < 0.05 and #, p < 0.05 as compared to control and CX3CL1 treatment.

Article Snippet: Three human OSCC cell lines (SCC4, SCC25 and SAS cells) were acquired from the Bioresource Collection and Research Center (BCRC).

Techniques: Expressing, Recombinant, Migration, Control

CX3CL1 triggers the phosphorylation of PLCβ/PKCα/c‐Src to signal the cell movement, migration and ICAM‐1 expression in human oral squamous cell carcinoma (OSCC) cells. (A‐C) Quantified result of cell movement, cell migration and ICAM‐1 expression with signalling inhibitors and CX3CL1 recombinant protein (30 ng/mL) treatment. (D‐E) Protein expression of phosphorylated PLCβ, PKCα and c‐Src with CX3CL1 recombinant protein (30 ng/mL) treatment in SCC4 cell and SAS cell. (F‐H) Quantified result of cell movement, cell migration and ICAM‐1 expression with PLCβ, PKCα or c‐Src siRNA and CX3CL1 recombinant protein (30 ng/mL) treatment. Results are expressed as the mean ± SD of four independent experiments. *, p < 0.05 and #, p < 0.05 as compared to control and CX3CL1 treatment.

Journal: Journal of Cellular and Molecular Medicine

Article Title: CX3CL1 induces cell migration and invasion through ICAM ‐1 expression in oral squamous cell carcinoma cells

doi: 10.1111/jcmm.17750

Figure Lengend Snippet: CX3CL1 triggers the phosphorylation of PLCβ/PKCα/c‐Src to signal the cell movement, migration and ICAM‐1 expression in human oral squamous cell carcinoma (OSCC) cells. (A‐C) Quantified result of cell movement, cell migration and ICAM‐1 expression with signalling inhibitors and CX3CL1 recombinant protein (30 ng/mL) treatment. (D‐E) Protein expression of phosphorylated PLCβ, PKCα and c‐Src with CX3CL1 recombinant protein (30 ng/mL) treatment in SCC4 cell and SAS cell. (F‐H) Quantified result of cell movement, cell migration and ICAM‐1 expression with PLCβ, PKCα or c‐Src siRNA and CX3CL1 recombinant protein (30 ng/mL) treatment. Results are expressed as the mean ± SD of four independent experiments. *, p < 0.05 and #, p < 0.05 as compared to control and CX3CL1 treatment.

Article Snippet: Three human OSCC cell lines (SCC4, SCC25 and SAS cells) were acquired from the Bioresource Collection and Research Center (BCRC).

Techniques: Phospho-proteomics, Migration, Expressing, Recombinant, Control

CX3CL1 promotes the phosphorylation of c‐Jun to upregulate the cell motility and ICAM‐1 expression in human oral squamous cell carcinoma (OSCC) cells. (A) Quantified result of CX3CL1‐induced cell movement with c‐Jun inhibitors (B) Quantified result of CX3CL1‐induced cell migration with c‐Jun inhibitors (C) Quantified result of CX3CL1‐induced ICAM‐1 expression with c‐Jun inhibitors (D) Protein expression of phosphorylated c‐Jun with CX3CL1 recombinant protein (30 ng/mL) treatment. (E) Quantified result of CX3CL1‐induced cell movement with c‐Jun siRNA treatment. (F) Quantified result of CX3CL1‐induced cell migration with c‐Jun siRNA treatment. (G) Quantified result of CX3CL1‐induced ICAM‐1 expression with c‐Jun siRNA treatment. Results are expressed as the mean ± SD of four independent experiments. *, p < 0.05 and #, p < 0.05 as compared to control and CX3CL1 treatment.

Journal: Journal of Cellular and Molecular Medicine

Article Title: CX3CL1 induces cell migration and invasion through ICAM ‐1 expression in oral squamous cell carcinoma cells

doi: 10.1111/jcmm.17750

Figure Lengend Snippet: CX3CL1 promotes the phosphorylation of c‐Jun to upregulate the cell motility and ICAM‐1 expression in human oral squamous cell carcinoma (OSCC) cells. (A) Quantified result of CX3CL1‐induced cell movement with c‐Jun inhibitors (B) Quantified result of CX3CL1‐induced cell migration with c‐Jun inhibitors (C) Quantified result of CX3CL1‐induced ICAM‐1 expression with c‐Jun inhibitors (D) Protein expression of phosphorylated c‐Jun with CX3CL1 recombinant protein (30 ng/mL) treatment. (E) Quantified result of CX3CL1‐induced cell movement with c‐Jun siRNA treatment. (F) Quantified result of CX3CL1‐induced cell migration with c‐Jun siRNA treatment. (G) Quantified result of CX3CL1‐induced ICAM‐1 expression with c‐Jun siRNA treatment. Results are expressed as the mean ± SD of four independent experiments. *, p < 0.05 and #, p < 0.05 as compared to control and CX3CL1 treatment.

Article Snippet: Three human OSCC cell lines (SCC4, SCC25 and SAS cells) were acquired from the Bioresource Collection and Research Center (BCRC).

Techniques: Phospho-proteomics, Expressing, Migration, Recombinant, Control

CX3CL1 promotes the translocation of c‐Jun and promoter binding of AP‐1 formation in human oral squamous cell carcinoma (OSCC) cells. (A) Immunofluorescent staining showed that c‐Jun translocated into the nucleus after cell were treated with CX3CL1; nuclear translocation was prevented when the cells were pre‐treated with CX3CR1 mAb, U73122, GF109203 or PP2. (B) Quantified analysis of c‐Jun activation with CX3CL1 using Western blot. (C) CX3CL1 treatment upregulated AP‐1 luciferase activity. (D) Quantified analysis of AP‐1 luciferase activity with specific inhibitors and CX3CL1 recombinant protein (30 ng/mL) treatment. (E) Chromatin immunoprecipitation analysis of c‐Jun and AP‐1 promoter binding site with neutralizing antibody and specific inhibitors. Results are expressed as the mean ± SD of four independent experiments. *, p < 0.05 and #, p < 0.05 as compared to control and CX3CL1 treatment.

Journal: Journal of Cellular and Molecular Medicine

Article Title: CX3CL1 induces cell migration and invasion through ICAM ‐1 expression in oral squamous cell carcinoma cells

doi: 10.1111/jcmm.17750

Figure Lengend Snippet: CX3CL1 promotes the translocation of c‐Jun and promoter binding of AP‐1 formation in human oral squamous cell carcinoma (OSCC) cells. (A) Immunofluorescent staining showed that c‐Jun translocated into the nucleus after cell were treated with CX3CL1; nuclear translocation was prevented when the cells were pre‐treated with CX3CR1 mAb, U73122, GF109203 or PP2. (B) Quantified analysis of c‐Jun activation with CX3CL1 using Western blot. (C) CX3CL1 treatment upregulated AP‐1 luciferase activity. (D) Quantified analysis of AP‐1 luciferase activity with specific inhibitors and CX3CL1 recombinant protein (30 ng/mL) treatment. (E) Chromatin immunoprecipitation analysis of c‐Jun and AP‐1 promoter binding site with neutralizing antibody and specific inhibitors. Results are expressed as the mean ± SD of four independent experiments. *, p < 0.05 and #, p < 0.05 as compared to control and CX3CL1 treatment.

Article Snippet: Three human OSCC cell lines (SCC4, SCC25 and SAS cells) were acquired from the Bioresource Collection and Research Center (BCRC).

Techniques: Translocation Assay, Binding Assay, Staining, Activation Assay, Western Blot, Luciferase, Activity Assay, Recombinant, Chromatin Immunoprecipitation, Control

Review

Structured Review

Images

Similar Products

Image Search Results